AIDS Therapy

Fuzeon to be available in Europe

Published in AIDS Weekly, March 24th, 2003

Roche and Trimeris, Inc., (TRMS) announced that F. Hoffmann-La Roche, Ltd., of Basel, Switzerland, will make the investigational HIV drug Fuzeon (enfuvirtide) available in European Union countries that elect to undertake a special license sales (SLS) program before regulatory approval is granted.

This European SLS program is part of the larger Fuzeon Early Access Program announced last year. The initiation of SLS programs will ensure that Fuzeon is made available as soon as possible for the growing number of Europeans living with HIV/AIDS who have limited treatment options. The SLS program price announced will be indicative of eventual global commercial prices;...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2003-03-24)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry